DiaMedica Therapeutics (DMAC) to Release Quarterly Earnings on Monday

DiaMedica Therapeutics (NASDAQ:DMACGet Free Report) is expected to announce its earnings results before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

DiaMedica Therapeutics Price Performance

Shares of DMAC stock opened at $5.77 on Friday. The firm has a market capitalization of $246.73 million, a price-to-earnings ratio of -10.30 and a beta of 1.52. The business has a fifty day moving average of $5.95 and a 200 day moving average of $5.07. DiaMedica Therapeutics has a 1 year low of $2.14 and a 1 year high of $6.82.

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

Featured Stories

Earnings History for DiaMedica Therapeutics (NASDAQ:DMAC)

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.